Prevalence of human papillomavirus and the correlation of HPV infection with cervical disease in Weihai, China

Objective: This study investigates the human papillomavirus (HPV) infection rate in female genital tracts, as well as the HPV genotype distribution and HPV correlation with cervical disease in Weihai, Shandong Province, China. Materials and Methods: A random sample of 9,460 volunteers was simultaneously screened using gene chips and examined by ThinPrep liquid-based cytology test (TCT). Cervical biopsy samples were collected from women with positive HPV-DNA and abnormal TCT for pathological diagnosis. Results: The overall HPV prevalence was 6.93% (656 of 9,460). Atotal of 753 subjects were infected with HPV subtypes (including multiple HPV infections). Of those with infections, 688 were infected with high-risk (HR) types (91.37%), and 65 were infected with low-risk subtypes (8.63%). The single-infection rate was 63.1%.The prevalence rates of HPV in women aged 20 to 39 years and 40 to 59 years were 7.29% and 6.71%, respectively. The most common genotype was HPV16. The HR genotypes were associated with cervical diseases such as atypical squamous cells of undetermined significance (ASCUS) (37.9%), atypical squamous cells high grade (ASC-H) (42.5%), low grade squamous intraepithelial lesion (LSIL) (50%), and high grade squamous intraepithelial lesion HSIL (66.7%). Cervical biopsy results show that the HPV detection rate increased in the following biopsy samples: cervical intraepithelial neoplasia (CIN) I (74.11%), CIN II (84.31%), CIN III (90.32%), and squamous-cell carcinoma (SCC) (100%). Conclusions: The HPV infection rate with associated cervical disease in Weihai is equal to those in foreign countries but is lower than the average rate in China. The prevalence of HPV was higher in young people. The most common HPV genotype was 16, followed by 52 and 58. HR HPV is the most probable infection factor for cervical diseases.

Human papillomavirus (HPV) Genotype; Cervical diseases; Liquid-based cytology.

[1] Zur Hausen H.: “Papillomaviruses and cancer: from basic studies to clinical application”. Nat Rev Cancer, 2002, 2, 342.

[2] Zur Hausen H.: “Human papillomaviruses and their possible role in squamous cell carcinomas”. Curr. Top. Microbiol. Immunol., 1977, 78, l.

[3] Burd E.M.: “Human papillomavirus and cervical cancer”. Clin Microbiol Rev, 2003, 16, 1.

[4] Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al.: “Management of women who test positive for highrisk types of human papillomavirus: the HART study”. Lancet, 2003; 362, 1871.

[5] Alam S., Bromberg-White J., McLaughlin-Drubin M., Sen E., Bodily JM., Meyers C.: “Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium”. Anticancer Res., 2005, 25, 765.

[6] Liu S.S., Leung R.C., Chan K.K., Cheung A.N., Ngan H.Y.: “Evaluation of a newly developed genoarray human papillomavirus (HPV) genotyping assay and comparison with the Roche linear array HPV genotyping assay”. Journal of Clinical Microbiology, 2010, 48, 758.

[7] Dai M., Bao Y.P., Li N., Clifford G.M., Vaccarella S., Snijders P.J., et al.: “Human papillomavirus infection in Shanxi Province, People’S Republic of China: a population-based study”. Br. J. Cancer., 2006, 95, 96.

[8] Wu R.F., Dai M., Qiao Y.L., Clifford G.M., Liu Z.H., Arslan A., et al.: “Human papillomavirus infection in women in Shenzhen City, People’s Republic of China. a population typical of recent Chinese urbanization”. Int. J. Cancer, 2007, 121, 1306.

[9] Li L.K., Dai M., Clifford G.M., Yao W.Q., Arslan A., Li N., et al.: “Human papillomavirus infection in Shenyang City, People’S Republic of China: a population-based study”. Br. J. Cancer., 2006, 95, 1593.

[10] Ye J., Cheng X., Chen X., Ye F., Lü W., Xie X.: “Prevalence and risk profile of cervical humn papillomavirus infection in Zhejiang Province,southeast China:a population-based study”. Virol. J., 2010, 7, 66.

[11] de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., et al.: “Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis”. Lancet Infect. Dis., 2007, 7, 453.

[12] Lee S.A., Kang D., Seo S.S., Jeong J.K., Yoo K.Y., Jeon Y.T., et al.: “Multiple HPV infction in cervical cancer screened by HPV DNA chip”. Cancer Lett., 2003, 198, 187.

[13] Molano M., Posso H., Weiderpass E., van den Brule A.J., RonderosM., Franceschi S., et al.: “Prevalence and derminants of HPV infection in women with normal cytology”. Br. J. Cancer., 2002, 87, 324.

[14] Rolón P.A., Smith J.S., Muñoz N., Klug S.J., Herrero R., Bosch X., et al.: “Human papillomavirus infection and invasive cervical cancer in Paraguay”. Int. J. Cancer, 2000, 85, 486.

[15] Lin M., Yang L.Y., Li L.J., Wu J.R., Peng Y.P., Luo Z.Y.: “Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province”. Aust. N. Z. J. Obstet. Gynaecol., 2008, 48, 189.

[16] Lai C.H., Chao A., Chang C.J., Chao F.Y., Huang H.J., Hsueh S., et al.: “Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan”. Int. J. Cancer., 2008, 123, 1685.

[17] An H.J., Cho N.H., Lee S.Y., Kim I.H., Lee C., Kim S.J., et al.: “Correlation of cervical carcinoma and precancerous lesions with human Papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method”. Cancer, 2003, 97, 1672.

[18] Kim C.J., Jeong J.K., Park M., Park T.S., Park T.C., Namkoong S.E., et al.: “HPV oligonucleotide microarray based detection of HPV genotypos in cervical neop lastic lesions”. Gynecol. Oncol., 2003, 89, 210.

[19] Chansaenroj J., Junyangdikul P., Chinchai T., Swangvaree S., Karalak A., Gemma N., et al.: “Large scale study of HPV genotypes in cervical cancer and different cytological cervical specimens in Thailand”. J. Med. Virol., 2013, 10, 1002.